Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBATROSS: Pemetrexed/Cisplatin in Advanced Soft Tissue Sarcoma
NCT04605770Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Dec 2020
- Primary completion
- Nov 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and Cisplatin micelle injection (HA132) in soft tissue sarcoma (STS), sponsored by Yonsei University. Primary endpoint: Progression-Free Survival rate at 12 weeks. Started Dec 2020; status: recruiting.
02
Drugs
pemetrexedCisplatin micelle injection (HA132)
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04605770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605770.